肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2014年
11期
757-760
,共4页
陈亦乐%李梅花%吴丽%唐真姿
陳亦樂%李梅花%吳麗%唐真姿
진역악%리매화%오려%당진자
DNA倍体分析%子宫颈癌%常规细胞学%筛查
DNA倍體分析%子宮頸癌%常規細胞學%篩查
DNA배체분석%자궁경암%상규세포학%사사
DNA ploidy analysis%Cervical cancer%Conventional cytology%Screen
目的 探讨DNA倍体分析在门诊患者子宫颈癌筛查中的应用价值.方法 对门诊行子宫颈癌筛查的2 692例女性就诊者同时进行液基薄层细胞学检查、DNA倍体分析,对其中可疑病变者840例进行子宫颈活组织检查.对参与子宫颈癌普查的妇女进行液基薄层制片,分别进行巴氏染色和Feulgen染色,由细胞学医师对巴氏染色片作常规细胞学诊断,应用全自动DNA倍体分析系统对Feulgen染色片进行自动扫描诊断.结果 840例患者子宫颈活组织病理检查结果分别为:慢性子宫颈炎554例(66.0％),子宫颈上皮内瘤变(CIN)Ⅰ 25例(3.0％),CINⅡ59例(7.0％),CINⅢ100例(11.9％),子宫颈癌102例(12.1％).DNA倍体分析中可见DNA异倍体细胞者(DNA异倍体细胞阳性)486例,未见DNA异倍体细胞者(DNA异倍体细胞阴性)354例;DNA异倍体细胞阳性、异倍体细胞≥3个用于筛查CINⅡ及以上病变的敏感度、特异度、阳性预测值、阴性预测值分别为91.9％和89.2％、58.5％和35.8％、49.4％和57.3％、94.1％和77.2％;采用液基薄层细胞学检查LSIL及以上用于筛查CINⅡ及以上病变的敏感度、特异度、阳性预测值、阴性预测值分别为40.2％、90.0％、39.6％和76.9％.结论 DNA倍体定量分析技术较常规细胞学敏感性高,可作为子宫颈癌普查的指标之一.
目的 探討DNA倍體分析在門診患者子宮頸癌篩查中的應用價值.方法 對門診行子宮頸癌篩查的2 692例女性就診者同時進行液基薄層細胞學檢查、DNA倍體分析,對其中可疑病變者840例進行子宮頸活組織檢查.對參與子宮頸癌普查的婦女進行液基薄層製片,分彆進行巴氏染色和Feulgen染色,由細胞學醫師對巴氏染色片作常規細胞學診斷,應用全自動DNA倍體分析繫統對Feulgen染色片進行自動掃描診斷.結果 840例患者子宮頸活組織病理檢查結果分彆為:慢性子宮頸炎554例(66.0％),子宮頸上皮內瘤變(CIN)Ⅰ 25例(3.0％),CINⅡ59例(7.0％),CINⅢ100例(11.9％),子宮頸癌102例(12.1％).DNA倍體分析中可見DNA異倍體細胞者(DNA異倍體細胞暘性)486例,未見DNA異倍體細胞者(DNA異倍體細胞陰性)354例;DNA異倍體細胞暘性、異倍體細胞≥3箇用于篩查CINⅡ及以上病變的敏感度、特異度、暘性預測值、陰性預測值分彆為91.9％和89.2％、58.5％和35.8％、49.4％和57.3％、94.1％和77.2％;採用液基薄層細胞學檢查LSIL及以上用于篩查CINⅡ及以上病變的敏感度、特異度、暘性預測值、陰性預測值分彆為40.2％、90.0％、39.6％和76.9％.結論 DNA倍體定量分析技術較常規細胞學敏感性高,可作為子宮頸癌普查的指標之一.
목적 탐토DNA배체분석재문진환자자궁경암사사중적응용개치.방법 대문진행자궁경암사사적2 692례녀성취진자동시진행액기박층세포학검사、DNA배체분석,대기중가의병변자840례진행자궁경활조직검사.대삼여자궁경암보사적부녀진행액기박층제편,분별진행파씨염색화Feulgen염색,유세포학의사대파씨염색편작상규세포학진단,응용전자동DNA배체분석계통대Feulgen염색편진행자동소묘진단.결과 840례환자자궁경활조직병리검사결과분별위:만성자궁경염554례(66.0％),자궁경상피내류변(CIN)Ⅰ 25례(3.0％),CINⅡ59례(7.0％),CINⅢ100례(11.9％),자궁경암102례(12.1％).DNA배체분석중가견DNA이배체세포자(DNA이배체세포양성)486례,미견DNA이배체세포자(DNA이배체세포음성)354례;DNA이배체세포양성、이배체세포≥3개용우사사CINⅡ급이상병변적민감도、특이도、양성예측치、음성예측치분별위91.9％화89.2％、58.5％화35.8％、49.4％화57.3％、94.1％화77.2％;채용액기박층세포학검사LSIL급이상용우사사CINⅡ급이상병변적민감도、특이도、양성예측치、음성예측치분별위40.2％、90.0％、39.6％화76.9％.결론 DNA배체정량분석기술교상규세포학민감성고,가작위자궁경암보사적지표지일.
Objective To investigate the value of DNA ploidy analysis in cervical cancer screening for outpatients.Methods 840 from 2 692 outpatients examed by Thin Prep cytology,DNA ploidy analysis were performed directed biopsy simultaneously.Sample were taken by cervix brush and transported into a fixative solution.Two slides were made from each sample for staining with Feulgen DNA specific staining and the other with Pap stained,respectively.The routine cytological diagnosis of Pap smear was done by cytology physicians,and the Feulgen staining tablets by the automated DNA ploidy analysis system.Results Among 840 cases,554 cases (66.0 ％) were histological diagnosed as chronic cervicitis,25 cases (3.0 ％) as cervical intraepithelial neoplasia (CIN) Ⅰ,59 cases (7.0 ％) as CIN Ⅱ,100 cases (11.9 ％) as CINⅢ and 102 cases (12.1％) as cervical invasive cancer by pathological biopsy.486 cases were observed with DNA heteroploid and 354 were not.The sensitivity,specificity,positive predictive values and negative predictive values of scanning CIN Ⅱ or more severe cervical diseases by DNA heteroploid positive or heteroploid ≥3 for were 91.9 ％ or 89.2 ％,58.5 ％ or 35.8 ％,49.4 ％ or 57.3 ％,94.1％ or 77.2 ％,respectively,while those of scanning equal or more than LSIS andthe above diseases by Thin Prep cytology were 40.2 ％,90.0 ％,39.6 ％ and 76.9 ％.Conclusion DNA ploidy analysis might be a useful tool for cervical cancer screening and has a competitive sensitivity compared with conventional cytology.
